Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

374 ARTÍCULOS , VIENDO DEL 256 AL 270

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition

Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, Mintun MA; 18F-AV-1451-A05 investigators.

Brain. 2017 Mar 1;140(3):748-763. doi: 10.1093/brain/aww334.

Vitamin E for Alzheimer's dementia and mild cognitive impairment

Farina N, Llewellyn D, Isaac MG, Tabet N.

Cochrane Database Syst Rev. 2017 Jan 27;1(1):CD002854. doi: 10.1002/14651858.CD002854.pub4.

Alzheimer's disease: time to focus on the brain, not just molecules

Husain M.

Brain. 2017 Feb;140(2):251-253. doi: 10.1093/brain/aww353.

Brain uptake and safety of Flutemetamol F 18 injection in Japanese subjects with probable Alzheimer's disease, subjects with amnestic mild cognitive impairment and healthy volunteers

Miki T, Shimada H, Kim JS, Yamamoto Y, Sugino M, Kowa H, Heurling K, Zanette M, Sherwin PF, Senda M.

Ann Nucl Med. 2017 Apr;31(3):260-272. doi: 10.1007/s12149-017-1154-7. Epub 2017 Feb 8.

[Alzheimer's disease and epilepsy]

Haussmann R, Mayer T, Schrempf W, Donix M.

Nervenarzt. 2017 Sep;88(9):1003-1009. doi: 10.1007/s00115-017-0286-2.

Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease

Geifman N, Brinton RD, Kennedy RE, Schneider LS, Butte AJ.

Alzheimers Res Ther. 2017 Feb 17;9(1):10. doi: 10.1186/s13195-017-0237-y.

Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

Fujino T, Yamada T, Asada T, Tsuboi Y, Wakana C, Mawatari S, Kono S.

EBioMedicine. 2017 Mar;17:199-205. doi: 10.1016/j.ebiom.2017.02.012. Epub 2017 Feb 24.

Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients

Ketter N, Brashear HR, Bogert J, Di J, Miaux Y, Gass A, Purcell DD, Barkhof F, Arrighi HM.

J Alzheimers Dis. 2017;57(2):557-573. doi: 10.3233/JAD-160216.

An update on the advancements in the treatment of agitation in Alzheimer's disease

Porsteinsson AP, Antonsdottir IM.

Expert Opin Pharmacother. 2017 Apr;18(6):611-620. doi: 10.1080/14656566.2017.1307340. Epub 2017 Mar 28.

Role of σ(1) Receptors in Learning and Memory and Alzheimer's Disease-Type Dementia

Maurice T, Goguadze N.

Adv Exp Med Biol. 2017;964:213-233. doi: 10.1007/978-3-319-50174-1_15.

[Alzheimer's disease]

Høgh P.

Ugeskr Laeger. 2017 Mar 20;179(12):V09160686.

Vitamin E for Alzheimer's dementia and mild cognitive impairment

Farina N, Llewellyn D, Isaac MGEKN, Tabet N.

Cochrane Database Syst Rev. 2017 Apr 18;4(4):CD002854. doi: 10.1002/14651858.CD002854.pub5.

Neurovascular Alterations in Alzheimer's Disease: Transporter Expression Profiles and CNS Drug Access

McInerney MP, Short JL, Nicolazzo JA.

AAPS J. 2017 Jul;19(4):940-956. doi: 10.1208/s12248-017-0077-5. Epub 2017 May 1.

Alzheimer's Disease and Histone Code Alterations

Narayan P, Dragunow M.

Adv Exp Med Biol. 2017;978:321-336. doi: 10.1007/978-3-319-53889-1_17.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias